• Keine Ergebnisse gefunden

Supplementary Figure 1

N/A
N/A
Protected

Academic year: 2022

Aktie "Supplementary Figure 1"

Copied!
1
0
0

Wird geladen.... (Jetzt Volltext ansehen)

Volltext

(1)

Supplementary Figure 1

Figure S1. Nuclear size estimation of PC3 xenograft sections. Nuclear size assessment in PC3

tumour cross-sections following 24h of treatment. Combined treatment of USMB and HT (246 kPa + 0 min; 246 kPa + 10 min; 246 kPa + 40 min; 246 kPa + 50 min; 570 kPa + 0 min; 570 kPa + 10 min; 570 kPa + 40 min and 570 kPa + 50 min) resulted in a significant difference in nuclear size compared to control (0 kPa + 0 min). An asterisk indicates P-values (p < 0.05) (*).

Referenzen

ÄHNLICHE DOKUMENTE

  Designed to measure the functional size in different domains (real-time, multi-layered software, process control and operating systems, business applications) using the

CTNNB1 site1F CAGGAAGGGATGGAAGGTCTC CTNNB1 site1R TCACGCAAAGGTGCATGATTT CTNNB1 site2F AGACGGAGGAAGGTCTGAGG CTNNB1 site2R GGCCATGTCCAACTCCATCA 100bp.. 250bp 500bp 1000bp

Supplementary Figure 1- cCAR T cell infusion leads to complete remission of stage IV diffuse large B cell lymphoma (DLBCL).. (A.) Patient was diagnosed with stage IV diffuse large

individ\i~'r'8 in our current time is related to the effects of the 'technological revolution' of the Nuclear Age. With the intro- duction of nuclear energy we entered a new era

*Underlines indicate the restriction enzyme sites. Supplementary

[r]

Multimodal assessment of results achieved after proximal optimization technique (POT) in provisional. A,B) View of well apposed stent proximal to the bifurcation by direct

Reports were retrieved matching the following search criteria: gastrointestinal stromal tumor AND KIT OR PDGFRA OR molecular biology OR therapy decision test.. Reports that